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Abstract Blockade of the renin-angiotensin-aldosterone
system (RAAS) offers superior renoprotection in the
treatment of patients with hypertension, but the efficacy of
RAAS inhibition strongly depends on sodium status,
presumably in relation to extracellular volume status.
Because assessing volume status by physical examination
is challenging, 24-hour urine collection and NT-proBNP
levels are useful tools for guiding volume management and
achieving sodium status targets.
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Introduction
Treatment of hypertension is of paramount importance in
chronic kidney disease (CKD). A series of intervention
trials in the 1990s demonstrated the superiority of blockade
of the renin-angiotensin-aldosterone system (RAAS) over
other antihypertensives for renoprotection. This superiority
was even apparent when similar blood pressure was
achieved, as first shown by the Ramipril Efficacy In
Nephropathy (REIN) study, and is most likely due to
specific renoprotective, antiproteinuric effects of RAAS
blockade. Accordingly, RAAS blockade has become the
therapy of choice for CKD, as recommended by the
available guidelines.
Yet prescribing of these drugs, evidence-based as it may
be, is not enough. The statistics on blood pressure control
in patients with CKD are still poor, and the number of
patients entering dialysis programs is constantly increasing.
Tools to increase the efficacy of the prevention regimens
based on RAAS inhibition are evidently necessary. It has
become evident that for an optimal renoprotective effect of
RAAS blockade, doses of these drugs must be high enough
to reduce proteinuria, which may require higher doses than
reduction of blood pressure alone. The hope that dual
blockade with an angiotensin-converting enzyme (ACE)
inhibitor and an angiotensin-receptor blocker (ARB) simul-
taneously might improve outcome in CKD has not been
fulfilled, and there are data to suggest that dual blockade
can even be harmful.
Interventions in pathways other than the RAAS are
under investigation and may contribute to better renopro-
tection in the future. Here, we want to focus on a strategy to
improve the efficacy of RAAS inhibitors that is being
neglected in clinical practice: the targeting of sodium status.
Sodium Status and RAAS Inhibition
The efficacy of RAAS inhibition strongly depends on the
actual sodium status of the patient. In fact, in circumstances
of sodium retention and thus expanded extracellular
volume, RAAS inhibiting drugs may be not effective at
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DOI 10.1007/s11906-011-0234-7all. At the other end of the spectrum, blood pressure and
renal function may drop dramatically in patients who are
volume-depleted. It appears that this volume dependency is
regarded as a disadvantage by many physicians. For
example, ACE inhibitors with a short half-life, such as
captopril, have been banned from some guidelines for
treating hypertensive emergencies because their effect is
considered too unpredictable, whereas in reality, the
variability of the response is probably largely explained
by the drug’s dependency on volume status. The combina-
tion of RAAS inhibition with severe volume depletion can
be dangerous, as typified by an 80-year-old woman who
enters the emergency ward with severe hypotension, acute
renal failure, and hyperkalemia because she did not stop her
ACE inhibitor when stricken with gastroenteritis. Does this
problem imply that sodium status should somehow be taken
into account or monitored in all patients for whom we
prescribe RAAS blockade? How many doctors routinely
consider the extracellular fluid status of their patients who
are receiving an ACE inhibitor or ARB?
Whereas the issue of safety is obviously relevant,
sodium status may be even more important from the point
of view of achieving therapeutic efficacy. In our experience,
obtained in patients with CKD as well as essential
hypertension, targeting sodium status provides a tremen-
dously powerful tool to increase the efficacy of RAAS
blockade.
Manipulating Sodium Status
For this purpose, sodium status can be manipulated in
clinical practice in well-established ways that include
dietary sodium restriction, the use of diuretics, and the
combination of these approaches. Actually, it should be
unnecessary to mention sodium restriction in this respect, as
it is included in all guidelines on treatment of hypertension
and should be widely adopted—but it is not. This is a
missed therapeutic opportunity, because even moderate
sodium restriction (reducing the average 160 to 200 mmol
usually consumed by the general population and patients
with CKD to about 100 mmol per day) will reduce blood
pressure by approximately 10 mm Hg on top of the effect
of RAAS blockade, and proteinuria will be reduced by
some 30%! A more or less similar effect can be obtained by
adding a diuretic to the RAAS blockade. A thiazide diuretic
is usually effective, or a loop diuretic may be used in
patients with more advanced CKD, in which thiazide
diuretics lose their efficacy. Of note, the effects of dietary
sodium restriction and diuretic treatment are additive,
enabling stepped volume titration. The aldosterone antag-
onists spironolactone and eplerenone offer an interesting
alternative. While acting as a diuretic, these agents also
may block the profibrotic effects of aldosterone at the organ
level (vasculature, kidney, heart). Whether this effect
translates into a better long-term outcome has not yet been
proven, however.
The beneficial effects on blood pressure and proteinuria
of targeting sodium excess during RAAS blockade have
repeatedly been confirmed in short-term studies. Of note,
recently presented post hoc data from randomized trials in
nondiabetic and diabetic renal patients indicate that sodium
excess is associated with worse long-term renal and
cardiovascular outcome through the blunted efficacy of
RAAS blockade. Although long-term prospective studies
are still lacking, this finding supports the case for better
management of sodium status and indicates that the benefit
of even modest sodium restriction can be expected to be
substantial, especially during RAAS blockade.
Monitoring Volume Status
To target sodium status, it is desirable that the intervention
can be titrated; that is, that patients requiring additional
correction of sodium excess can be identified and moni-
tored. If blood pressure and proteinuria reach target values
after the institution of sodium restriction and/or diuretic
use, the intervention is clearly effective and no additional
measures are required. All too often, however, clinical
dilemmas arise when blood pressure control remains
suboptimal, residual proteinuria remains, or both. Is volume
correction still inadequate in this situation, and should it
invariably be intensified? As a rule of thumb, residual ankle
edema suggests persistent volume excess, but edema is not
universally present in CKD patients (even those with
proteinuria in the nephrotic range), and edema can occur
in the absence of systemic volume overload.
Nevertheless, we are not completely empty-handed. Two
simple tools can help to monitor the efficacy of volume
targeting: 24-hour urine collection and the measurement of
N-terminal pro-brain natriuretic peptide (NT-proBNP). In
our outpatient clinic, CKD patients collect 24-hour urines
as part of their standard nephrologic care. These collections
provide valuable information not only on diet (i.e., intake of
sodium, potassium, and protein) but also on proteinuria and
creatine clearance. Whereas 24-hour urine collection is
often regarded with skepticism among clinicians because of
its alleged inaccuracy, we take the point of view that the
grim prognosis of CKD and the efforts required to
implement a persistent change in dietary habits warrant
proper instruction and training of the patient to this
purpose, as an investment in future health. In our
experience, patients are comfortable in doing these collec-
tions three times a year, as they gain useful feedback in
return that helps them to make their efforts to reduce dietary
398 Curr Hypertens Rep (2011) 13:397–399sodium (and protein, if applicable) more successful. The
24-hour excretion of creatinine should be in line with body
dimensions and estimated muscle mass and should be stable
in consecutive collections, providing an adequate check for
appropriate collection. However, one should be aware that
even when sodium excretion (and hence, sodium intake) is
acceptable, body sodium can be too high, as the state of
sodium balance is governed not only by intake but also by
the avidity of sodium-retaining mechanisms.
Therefore, we propose the use of NT-proBNP levels as
an additional tool to guide volume management. NT-
proBNP is an indicator of the cardiac response to volume
overload and has proven useful in patients with heart
failure. We hypothesize that it also may be useful to guide
volume management in CKD. We have found that NT-
proBNP levels are mildly increased in CKD patients
without cardiac dysfunction, yet are well below the levels
usually observed in heart failure. It is likely that the mildly
increased NT-proBNP in CKD patients with proteinuria
reflects their state of volume expansion. When we treated
these patients with incremental volume intervention measures
(sodium restriction and hydrochlorothiazide) added to RAAS
blockade, the NT-proBNP levels were stepwise reduced
towards normal. Interestingly, during each of the titration
steps, an NT-proBNP level above normal predicted a good
therapeutic response of blood pressure and proteinuria to the
subsequent volume-intervention step. Once NT-proBNP was
normalized, further volume depletion produced no added
therapeutic benefit. We are currently investigating whether
NT-proBNP can guide volume management in the clinical
setting of renoprotection and could prevent potential adverse
eventsofvolumedepletion,suchas symptomatichypotension,
clinically relevant impairment of renal function, or gout. This
tool may not only help to avoid acute adverse clinical effects,
but also may help in titrating the patient to a volume status that
affords optimization of the clinical efficacy of RAAS
blockade, while avoiding possible long-term adverse effects
of overzealous volume targeting, such as aggravation of
chronicrenalhypoxialeadingtorenalfibrosis,orthenongouty
adverse effects of elevated uric acid on the cardiorenal
risk profile.
Conclusions
The efficacy of RAAS inhibition strongly depends on
sodium status, presumably in relation to extracellular
volume status. Whether nonosmotic storage of sodium is
also relevant in this respect remains to be investigated. As
assessing volume status by physical examination remains a
major challenge for any clinician treating patients with
hypertension and kidney disease, NT-proBNP may prove to
bea helpful tool inguidingvolumemanagement, and 24-hour
urinecollectionaddsvaluableinformationondiet,proteinuria,
and creatine clearance.
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